Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.

McCague AF, Raraigh KS, Pellicore MJ, Davis-Marcisak EF, Evans TA, Han ST, Lu Z, Joynt AT, Sharma N, Castellani C, Collaco JM, Corey M, Lewis MH, Penland CM, Rommens JM, Stephenson AL, Sosnay PR, Cutting GR.

Am J Respir Crit Care Med. 2019 May 1;199(9):1116-1126. doi: 10.1164/rccm.201901-0145OC.

PMID:
30888834
2.

Effect of Roasting on Oligosaccharide Abundance in Arabica Coffee Beans.

Tian T, Freeman S, Corey M, German JB, Barile D.

J Agric Food Chem. 2018 Sep 26;66(38):10067-10076. doi: 10.1021/acs.jafc.8b02641. Epub 2018 Sep 13.

PMID:
30175920
3.

Reference percentiles of FEV1 for the Canadian cystic fibrosis population: comparisons across time and countries.

Kim SO, Corey M, Stephenson AL, Strug LJ.

Thorax. 2018 May;73(5):446-450. doi: 10.1136/thoraxjnl-2017-210899. Epub 2018 Feb 6.

PMID:
29434047
4.

Select early type IA endoleaks after endovascular aneurysm repair will resolve without secondary intervention.

O'Donnell TFX, Corey MR, Deery SE, Tsougranis G, Maruthi R, Clouse WD, Cambria RP, Conrad MF.

J Vasc Surg. 2018 Jan;67(1):119-125. doi: 10.1016/j.jvs.2017.05.096.

PMID:
29268912
5.

Chemical Characterization of Potentially Prebiotic Oligosaccharides in Brewed Coffee and Spent Coffee Grounds.

Tian T, Freeman S, Corey M, German JB, Barile D.

J Agric Food Chem. 2017 Apr 5;65(13):2784-2792. doi: 10.1021/acs.jafc.6b04716. Epub 2017 Mar 28.

PMID:
28318250
6.

The presentation and management of aneurysms of the pancreaticoduodenal arcade.

Corey MR, Ergul EA, Cambria RP, Patel VI, Lancaster RT, Kwolek CJ, Conrad MF.

J Vasc Surg. 2016 Dec;64(6):1734-1740. doi: 10.1016/j.jvs.2016.05.067.

7.

The natural history of splanchnic artery aneurysms and outcomes after operative intervention.

Corey MR, Ergul EA, Cambria RP, English SJ, Patel VI, Lancaster RT, Kwolek CJ, Conrad MF.

J Vasc Surg. 2016 Apr;63(4):949-57. doi: 10.1016/j.jvs.2015.10.066. Epub 2016 Jan 11.

8.

Bias in CFTR screening panels.

Sosnay PR, Castellani C, Penland CM, Rommens JM, Lewis M, Raraigh KS, Corey M, Cutting GR.

Genet Med. 2016 Feb;18(2):209. doi: 10.1038/gim.2015.105. Epub 2015 Oct 29. No abstract available.

9.

Children after fontan have strength and body composition similar to healthy peers and can successfully participate in daily moderate-to-vigorous physical activity.

Longmuir PE, Corey M, Faulkner G, Russell JL, McCrindle BW.

Pediatr Cardiol. 2015 Apr;36(4):759-67. doi: 10.1007/s00246-014-1080-6. Epub 2014 Dec 12.

PMID:
25500696
10.

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.

Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, Grasemann H, Zlosnik J, Speert D, Corey M, Stanojevic S, Matukas L, Leahy TR, Shih S, Waters V.

J Cyst Fibros. 2015 Mar;14(2):262-6. doi: 10.1016/j.jcf.2014.09.013. Epub 2014 Oct 30.

11.

The 50 most influential original articles in vascular surgery during the last 25 years.

Stegall F, Corey M, Dattilo J.

J Vasc Surg. 2014 Sep;60(3):786-91. doi: 10.1016/j.jvs.2014.05.010. Epub 2014 Jun 26.

12.

European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis.

Stern M, Bertrand DP, Bignamini E, Corey M, Dembski B, Goss CH, Pressler T, Rault G, Viviani L, Elborn JS, Castellani C.

J Cyst Fibros. 2014 May;13 Suppl 1:S43-59. doi: 10.1016/j.jcf.2014.03.011. Review.

13.

Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis?

Ooi CY, Dupuis A, Gonska T, Ellis L, Ni A, Jarvi K, Martin S, Ray P, Steele L, Kortan P, Dorfman R, Solomon M, Zielenski J, Corey M, Tullis E, Durie P.

Ann Am Thorac Soc. 2014 May;11(4):562-70. doi: 10.1513/AnnalsATS.201311-412OC.

PMID:
24697796
14.

Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis.

Schneiderman JE, Wilkes DL, Atenafu EG, Nguyen T, Wells GD, Alarie N, Tullis E, Lands LC, Coates AL, Corey M, Ratjen F.

Eur Respir J. 2014 Mar;43(3):817-23. doi: 10.1183/09031936.00055513. Epub 2013 Oct 31.

15.

Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?

Ooi CY, Dupuis A, Ellis L, Jarvi K, Martin S, Ray PN, Steele L, Kortan P, Gonska T, Dorfman R, Solomon M, Zielenski J, Corey M, Tullis E, Durie P.

Thorax. 2014 Mar;69(3):254-60. doi: 10.1136/thoraxjnl-2013-203832. Epub 2013 Oct 21.

PMID:
24149827
16.

Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.

Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, Masica DL, Karchin R, Millen L, Thomas PJ, Patrinos GP, Corey M, Lewis MH, Rommens JM, Castellani C, Penland CM, Cutting GR.

Nat Genet. 2013 Oct;45(10):1160-7. doi: 10.1038/ng.2745. Epub 2013 Aug 25.

17.

BMP-2 adverse reactions treated with human dose equivalent dexamethasone in a rodent model of soft-tissue inflammation.

Xiong C, Daubs MD, Montgomery SR, Aghdasi B, Inoue H, Tian H, Suzuki A, Tan Y, Hayashi T, Ruangchainikom M, Chai T, Corey M, Wang JC.

Spine (Phila Pa 1976). 2013 Sep 1;38(19):1640-7. doi: 10.1097/BRS.0b013e31829cf348.

PMID:
23715023
18.

Home-based rehabilitation enhances daily physical activity and motor skill in children who have undergone the Fontan procedure.

Longmuir PE, Tyrrell PN, Corey M, Faulkner G, Russell JL, McCrindle BW.

Pediatr Cardiol. 2013 Jun;34(5):1130-51. doi: 10.1007/s00246-012-0618-8. Epub 2013 Jan 25.

PMID:
23354148
19.

Suffering assessment: a review of available instruments for use in palliative care.

Krikorian A, Limonero JT, Corey MT.

J Palliat Med. 2013 Feb;16(2):130-42. doi: 10.1089/jpm.2012.0370. Epub 2013 Jan 25. Review.

PMID:
23350831
20.

Patient education level affects functionality and long term mortality after major lower extremity amputation.

Corey MR, St Julien J, Miller C, Fisher B, Cederstrand SL, Nylander WA, Guzman RJ, Dattilo JB.

Am J Surg. 2012 Nov;204(5):626-30. doi: 10.1016/j.amjsurg.2012.07.018. Epub 2012 Aug 18.

21.

Diverging destinies: maternal education and the developmental gradient in time with children.

Kalil A, Ryan R, Corey M.

Demography. 2012 Nov;49(4):1361-83. doi: 10.1007/s13524-012-0129-5.

22.

Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis.

Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, Lin F, Dorfman R, Busson PF, Parekh RV, Zelenika D, Blackman SM, Corey M, Doshi VK, Henderson L, Naughton KM, O'Neal WK, Pace RG, Stonebraker JR, Wood SD, Wright FA, Zielenski J, Clement A, Drumm ML, Boëlle PY, Cutting GR, Knowles MR, Durie PR, Strug LJ.

Nat Genet. 2012 May;44(5):562-9. doi: 10.1038/ng.2221.

23.

Pattern of growth of very low birth weight preterm infants, assessed using the WHO Growth Standards, is associated with neurodevelopment.

Nash A, Dunn M, Asztalos E, Corey M, Mulvihill-Jory B, O'Connor DL.

Appl Physiol Nutr Metab. 2011 Aug;36(4):562-9. doi: 10.1139/h11-059. Epub 2011 Aug 19.

PMID:
21854163
24.

Stability and anti-glycation properties of intermediate moisture apple products fortified with green tea.

Lavelli V, Corey M, Kerr W, Vantaggi C.

Food Chem. 2011 Jul 15;127(2):589-95. doi: 10.1016/j.foodchem.2011.01.047. Epub 2011 Jan 18.

PMID:
23140704
25.

Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2.

Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM, Corey M, Dorfman R, Goddard K, Green D, Kent JW Jr, Lange EM, Lee S, Li W, Luo J, Mayhew GM, Naughton KM, Pace RG, Paré P, Rommens JM, Sandford A, Stonebraker JR, Sun W, Taylor C, Vanscoy LL, Zou F, Blangero J, Zielenski J, O'Neal WK, Drumm ML, Durie PR, Knowles MR, Cutting GR.

Nat Genet. 2011 Jun;43(6):539-46. doi: 10.1038/ng.838. Epub 2011 May 22.

26.

Evaluation of the disease liability of CFTR variants.

Sosnay PR, Castellani C, Corey M, Dorfman R, Zielenski J, Karchin R, Penland CM, Cutting GR.

Methods Mol Biol. 2011;742:355-72. doi: 10.1007/978-1-61779-120-8_21.

PMID:
21547743
27.

Cystic fibrosis newborn screening does not delay the identification of cystic fibrosis in children with negative results.

Maclean JE, Solomon M, Corey M, Selvadurai H.

J Cyst Fibros. 2011 Sep;10(5):333-7. doi: 10.1016/j.jcf.2011.04.002. Epub 2011 May 4.

28.

A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies.

Taylor C, Commander CW, Collaco JM, Strug LJ, Li W, Wright FA, Webel AD, Pace RG, Stonebraker JR, Naughton K, Dorfman R, Sandford A, Blackman SM, Berthiaume Y, Paré P, Drumm ML, Zielenski J, Durie P, Cutting GR, Knowles MR, Corey M.

Pediatr Pulmonol. 2011 Sep;46(9):857-69. doi: 10.1002/ppul.21456. Epub 2011 Apr 1.

29.

Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis.

Leahy TR, Yau YC, Atenafu E, Corey M, Ratjen F, Waters V.

Pediatr Pulmonol. 2011 May;46(5):489-96. doi: 10.1002/ppul.21383. Epub 2011 Feb 17.

PMID:
21337531
30.

Factors associated with the physical activity level of children who have the Fontan procedure.

Longmuir PE, Russell JL, Corey M, Faulkner G, McCrindle BW.

Am Heart J. 2011 Feb;161(2):411-7. doi: 10.1016/j.ahj.2010.11.019.

PMID:
21315227
31.

Cystic fibrosis modifier genes related to Pseudomonas aeruginosa infection.

Park JE, Yung R, Stefanowicz D, Shumansky K, Akhabir L, Durie PR, Corey M, Zielenski J, Dorfman R, Daley D, Sandford AJ.

Genes Immun. 2011 Jul;12(5):370-7. doi: 10.1038/gene.2011.5. Epub 2011 Jan 27.

PMID:
21270830
32.

Higher risk of hospitalization among females with cystic fibrosis.

Stephenson A, Hux J, Tullis E, Austin PC, Corey M, Ray J.

J Cyst Fibros. 2011 Mar;10(2):93-9. doi: 10.1016/j.jcf.2010.10.005. Epub 2010 Dec 4.

33.

TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis.

Blohmke CJ, Park J, Hirschfeld AF, Victor RE, Schneiderman J, Stefanowicz D, Chilvers MA, Durie PR, Corey M, Zielenski J, Dorfman R, Sandford AJ, Daley D, Turvey SE.

J Immunol. 2010 Dec 15;185(12):7731-8. doi: 10.4049/jimmunol.1001513. Epub 2010 Nov 10.

34.

Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis.

Dorfman R, Taylor C, Lin F, Sun L, Sandford A, Paré P, Berthiaume Y, Corey M, Durie P, Zielenski J; Members of Canadian Consortium for CF Genetic Studies.

Pediatr Pulmonol. 2011 Apr;46(4):385-92. doi: 10.1002/ppul.21372. Epub 2010 Oct 21.

PMID:
20967843
35.

Socioeconomic status and risk of hospitalization among individuals with cystic fibrosis in Ontario, Canada.

Stephenson A, Hux J, Tullis E, Austin PC, Corey M, Ray J.

Pediatr Pulmonol. 2011 Apr;46(4):376-84. doi: 10.1002/ppul.21368. Epub 2010 Oct 21.

PMID:
20967840
36.

Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis.

Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, Freedman SD, Zielenski J, Berthiaume Y, Corey M, Schibli S, Tullis E, Durie PR.

Gastroenterology. 2011 Jan;140(1):153-61. doi: 10.1053/j.gastro.2010.09.046. Epub 2010 Nov 9.

PMID:
20923678
37.

Understanding the population structure of North American patients with cystic fibrosis.

Li W, Sun L, Corey M, Zou F, Lee S, Cojocaru AL, Taylor C, Blackman SM, Stephenson A, Sandford AJ, Dorfman R, Drumm ML, Cutting GR, Knowles MR, Durie P, Wright FA, Strug LJ.

Clin Genet. 2011 Feb;79(2):136-46. doi: 10.1111/j.1399-0004.2010.01502.x.

38.

Formulation of a dry green tea-apple product: study on antioxidant and color stability.

Lavelli V, Vantaggi C, Corey M, Kerr W.

J Food Sci. 2010 Mar;75(2):C184-90. doi: 10.1111/j.1750-3841.2009.01489.x.

39.

Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene?

Dorfman R, Nalpathamkalam T, Taylor C, Gonska T, Keenan K, Yuan XW, Corey M, Tsui LC, Zielenski J, Durie P.

Clin Genet. 2010 May;77(5):464-73. doi: 10.1111/j.1399-0004.2009.01351.x. Epub 2009 Jan 6.

PMID:
20059485
40.

Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors.

Radhakrishnan DK, Yau Y, Corey M, Richardson S, Chedore P, Jamieson F, Dell SD.

Pediatr Pulmonol. 2009 Nov;44(11):1100-6. doi: 10.1002/ppul.21106.

PMID:
19830845
41.

Genetic modifiers of liver disease in cystic fibrosis.

Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group.

JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295.

42.

Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results.

Dorfman R, Li W, Sun L, Lin F, Wang Y, Sandford A, Paré PD, McKay K, Kayserova H, Piskackova T, Macek M, Czerska K, Sands D, Tiddens H, Margarit S, Repetto G, Sontag MK, Accurso FJ, Blackman S, Cutting GR, Tsui LC, Corey M, Durie P, Zielenski J, Strug LJ.

Hum Genet. 2009 Dec;126(6):763-78. doi: 10.1007/s00439-009-0724-8.

43.

Does the Macroduct collection system reliably define sweat chloride concentration in subjects with intermediate results?

Rose JB, Ellis L, John B, Martin S, Gonska T, Solomon M, Tullis E, Corey M, Adeli K, Durie PR.

Clin Biochem. 2009 Aug;42(12):1260-4. doi: 10.1016/j.clinbiochem.2009.05.001. Epub 2009 May 13.

PMID:
19445912
44.

Modern antifungal therapy for neutropenic fever.

Corey M.

Curr Infect Dis Rep. 2009 Jan;11(1):29-34.

PMID:
19094822
45.

An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years.

Hodson ME, Simmonds NJ, Warwick WJ, Tullis E, Castellani C, Assael B, Dodge JA, Corey M; International Study Of Aging In Cystic Fibrosis.

J Cyst Fibros. 2008 Nov;7(6):537-42. doi: 10.1016/j.jcf.2008.06.003. Epub 2008 Aug 19.

46.

Functional outcome after thoracoabdominal aneurysm repair.

Crawford RS, Pedraza JD, Chung TK, Corey M, Conrad MF, Cambria RP.

J Vasc Surg. 2008 Oct;48(4):828-35. doi: 10.1016/j.jvs.2008.05.018. Epub 2008 Jul 26.

47.

One-stage design is empirically more powerful than two-stage design for family-based genome-wide association studies.

Rohlfs RV, Taylor C, Mirea L, Bull SB, Corey M, Anderson AD.

BMC Proc. 2007;1 Suppl 1:S137. Epub 2007 Dec 18.

48.

Field testing of the 2006 World Health Organization growth charts from birth to 2 years: assessment of hospital undernutrition and overnutrition rates and the usefulness of BMI.

Nash A, Secker D, Corey M, Dunn M, O'Connor DL.

JPEN J Parenter Enteral Nutr. 2008 Mar-Apr;32(2):145-53. doi: 10.1177/0148607108314386.

PMID:
18407907
49.

Novel Kv3 glycoforms differentially expressed in adult mammalian brain contain sialylated N-glycans.

Schwalbe RA, Corey MJ, Cartwright TA.

Biochem Cell Biol. 2008 Feb;86(1):21-30. doi: 10.1139/o07-152.

PMID:
18364742
50.

Complex two-gene modulation of lung disease severity in children with cystic fibrosis.

Dorfman R, Sandford A, Taylor C, Huang B, Frangolias D, Wang Y, Sang R, Pereira L, Sun L, Berthiaume Y, Tsui LC, Paré PD, Durie P, Corey M, Zielenski J.

J Clin Invest. 2008 Mar;118(3):1040-9. doi: 10.1172/JCI33754.

Supplemental Content

Support Center